Evidence map›Paper›PMID 37166354›Full record

ReviewJournal of neurotrauma2023

Interleukin-6 in Traumatic Brain Injury: A Janus-Faced Player in Damage and Repair.

Prajwal Ciryam, Volodymyr Gerzanich, J Marc Simard

Open access · greenAbstract readReview
In one paragraph

Review in Journal of neurotrauma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pathway-level proteomics identifies subcellular trafficking dysregulation as a molecular signature in severe traumatic brain injury.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Prajwal CiryamShock Trauma Neurocritical Care, Program in Trauma, R Adams Cowley Shock Trauma Center, University of Maryland Medical System, Baltimore, Maryland, USA.
Volodymyr GerzanichDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
J Marc SimardDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
University of Maryland, Baltimore · US

Funding

Sulfonylurea receptor 1 (SUR1)- A novel therapeutic target in ischemic strokeR01HL082517 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SIMARD, J. MARC · 2006 to 2021
$5.6M
Aquaporin-4 regulation by NCX1 in post-ischemic brain swellingR01NS127986 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI J. Marc Simard · 2022 to 2026
$1.9M
Fn14, non-canonical NF-kappaB and downstream signaling in neuropathic painR01NS105633 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI SIMARD, J. MARC · 2018 to 2022
$1.9M
Non-canonical NF-kappaB signaling and Sur1-Trpm4 in traumatic brain injuryR01NS102589 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI SIMARD, J. MARC · 2017 to 2021
$1.7M
NHLBI NIH HHS R01 HL082517NINDS NIH HHS R01 NS102589NINDS NIH HHS R01 NS105633NINDS NIH HHS R01 NS127986
6 · The paper itself

Abstract

Traumatic brain injury (TBI) is a common and often devastating illness, with wide-ranging public health implications. In addition to the primary injury, victims of TBI are at risk for secondary neurological injury by numerous mechanisms. Current treatments are limited and do not target the profound immune response associated with injury. This immune response reflects a convergence of peripheral and central nervous system-resident immune cells whose interaction is mediated in part by a disruption in the blood-brain barrier (BBB). The diverse family of cytokines helps to govern this communication and among these, Interleukin (IL)-6 is a notable player in the immune response to acute neurological injury. It is also a well-established pharmacological target in a variety of other disease contexts. In TBI, elevated IL-6 levels are associated with worse outcomes, but the role of IL-6 in response to injury is double-edged. IL-6 promotes neurogenesis and wound healing in animal models of TBI, but it may also contribute to disruptions in the BBB and the progression of cerebral edema. Here, we review IL-6 biology in the context of TBI, with an eye to clarifying its controversial role and understanding its potential as a target for modulating the immune response in this disease.

Indexed as

Brain EdemaBrain Injuries, TraumaticAnimalsBlood-Brain BarrierCytokinesDisease Models, AnimalInterleukin-6CytokinesInterleukin-6cytokinesIL-6immunologyimmunomodulationtraumatic brain injury

Identifiers

PMID37166354
PMCPMC10649197
OpenAlexW4376132906

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.